CD274 and neoplasm: Nivolumab is one of the immune-checkpoint inhibitors (ICIs) that inhibits the programmed death 1 (PD-1) and the programmed death ligand 1 (PD-L1) pathways and releases effector T cells as a defense against tumor cells.